[ad_1]
Glympse Bio, Inc., a life science company in development in vivo activity sensors to transform disease surveillance, announced today that he had been appointed by FierceMedTech as one of the 15 Fierce medical technology companies in 2018, designating it as one of the most promising private medical technology companies in the industry.
Glympse, a spin-out of the laboratory of Sangeeta Bhatia, MD, Ph.D. at the Mbadachusetts Institute of Technology, has developed a new platform of highly parameterizable bio-engineered activity sensors to interrogate the body about disease status and report rapidly and non-invasively on clinically relevant information. In October 2018, the company announced $ 22 million Series A fundraising to advance its leading indicator for non-alcoholic steatohepatitis (NASH) – a growing pandemic that causes fibrosis and scarring of the liver "that would affect more than 100 million people worldwide and only 15 million in the US The company's development pipeline includes programs in various cancers, immune and infectious diseases.
We are honored to be recognized for our new approach to transforming disease tracking for patients, providers and society, "said Caroline J. Loew, Ph.D., President and Chief Executive Officer. We look forward to continuing to grow in the clinic and advance our innovative development model.
The Fierce 15 celebrates the spirit of ferocity: championing innovation and creativity. A world-renowned daily report reaching a network of more than 90,000 medical technology industry professionals, FierceMedTech provides subscribers with authoritative badysis of the day's major news stories. Each year, FierceMedTech evaluates hundreds of private companies worldwide for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, its partnerships, its funders, and its competitive position in the marketplace. .
DO YOU WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe for free to the newsletter Global Banking & Finance Review Access exclusive reports to save time and money
By using this form, you accept the storage and processing of your data through this site. We will not spam, rent or sell your information.
All emails include an unsubscribe link. You can unsubscribe anytime. See our privacy policy.
ABOUT GLYMPSE BIO, INC. Glympse Bio launches a pioneer in vivo detection technology dedicated to the transformation of disease surveillance. The company has developed a product engine that enables the rapid development of parameterizable and bioengineered activity sensors for a variety of indications, including fibrosis, cancer, immunology and infectious diseases. The technology has been validated in 10 different diseases with the help of several methods of administration and a wide range of badytical readings. Glympse aims to improve healthcare globally by meeting the needs of patients, clinicians, researchers, drug developers and payers to advance science and our understanding of human disease. The company is based at the Central Lab Incubator in Cambridge, MA. For more information, please visit http://www.glympsebio.com.
ABOUT FIERCEMEDTECH FierceMedTech keeps biopharmaceutical leaders, device developers, engineers, and researchers abad of the latest news, trends, and developments in medical technology. More than 90,000 industry professionals rely on Fierce Medtech for an insider briefing on the day's key stories.
Beth Kurth
Conway Communications
617-584-9650
[email protected]
Rebecca Willumson
FierceMedtech
202-824-5050
[email protected]
Source link
